Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Actusnews Wire
610 Leser
Artikel bewerten:
(2)

BOIRON: Boiron Laboratories announce a reorganisation project

Laboratoires Boiron, a French company and world leader in homeopathic medicines, today announced a major reorganization project in France.

For the past two years, the virulent, unjustified and repeated attacks against homeopathy in France have weighed heavily on our company, which has seen its activity and economic results decline sharply.

While our production is 100% French and we generate 56% of our sales in France, the brutal decision of the Ministry of Solidarity and Health to delist homeopathic medicines as of January 1, 2021, constitutes a real breakthrough that has led our company to announce the following reorganization project:

  • The closure of the Montrichard production site near Tours,
  • The closure of 12 preparation-distribution establishments out of the 27 we have in France: Avignon, Belfort, Brest, Grenoble, Limoges, Niort, Paris-Bois d'Arcy, Paris-Ivry, Pau, Rouen, Strasbourg and Toulon,
  • The resizing of the production and preparation-distribution teams on the retained sites,
  • The reorganisation of the sales teams.

This plan would result in the elimination of 646 positions and the creation of 134 positions.

We will do our utmost to limit the social impact of this reorganization project while respecting our social heritage.

This planned organisation should make it possible to preserve our quality of service to healthcare professionals and patients.

Christine Place, Deputy Managing Director in charge of Human Resources :

« We are going to do everything we can to support each employee in his or her career path. We will put all our energy into alleviating, as far as possible, the individual difficulties of our employees. We will work with the trade unions on two fronts: firstly, to find the most appropriate support measures to enable each employee to find a job in his or her region, since geographical mobility is not always possible; secondly, to support the many employees at the end of their careers so that they can make the most of their human and professional qualities. It will therefore be necessary to think outside the box to think differently and allow everyone to be supported and assisted in the best possible way. »

Valérie Lorentz-Poinsot, CEO of Laboratoires Boiron :

« We have always been particularly attentive to the respect of each of our employees. It is therefore with great bitterness that we must today present an unprecedented reorganization project. In a context of sharply declining business activity in France, we must react without delay and take decisions, which are certainly very difficult, but which will be able to ensure the long-term survival of our company. »

Our medicines are fully in line with the need expressed by millions of patients around the world for a more humane, respectful and sustainable medicine. As stated by the World Health Organization, « it is important that Member States consider how to further integrate traditional and complementary medicine into their health systems and universal health coverage plans1. »

For these reasons, for the 72 % of French people and for the 50 % of health professionals who are convinced of the benefits of homeopathy2, we will pursue with determination all the steps and actions to obtain continued reimbursement of homeopathic medicines.

Laboratoires BOIRON

Person responsible for financial information: Valérie Lorentz-Poinsot
Contact for financial information: Fabrice Rey
Investor relations: +33 (0) 4.78.45.63.43 - e-mail: boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com

1 WHO Global Strategy for Traditional Medicine 2014-2023, p. 49
2 Odoxa, Health Barometer 360 (2019)

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: nW5yZcabaWaVmppuZ5ibbJNobGmXw2DFmmmemGVslJiaaJuRm25lmpmeZm9jmWxt
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-62477-boi-110320-projet-de-reorganisation-gb.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2020 Actusnews Wire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.